CA2762600C - Use of dynamin ring stabilizers - Google Patents

Use of dynamin ring stabilizers Download PDF

Info

Publication number
CA2762600C
CA2762600C CA2762600A CA2762600A CA2762600C CA 2762600 C CA2762600 C CA 2762600C CA 2762600 A CA2762600 A CA 2762600A CA 2762600 A CA2762600 A CA 2762600A CA 2762600 C CA2762600 C CA 2762600C
Authority
CA
Canada
Prior art keywords
dynamin
ring
actin
stabilizer
dynamin ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2762600A
Other languages
English (en)
French (fr)
Other versions
CA2762600A1 (en
Inventor
Phillip J. Robinson
Sanja Sever
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Children's Medical Research Institute
Original Assignee
Children's Medical Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Children's Medical Research Institute filed Critical Children's Medical Research Institute
Publication of CA2762600A1 publication Critical patent/CA2762600A1/en
Application granted granted Critical
Publication of CA2762600C publication Critical patent/CA2762600C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA2762600A 2009-05-21 2010-05-21 Use of dynamin ring stabilizers Active CA2762600C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18026109P 2009-05-21 2009-05-21
US61/180,261 2009-05-21
PCT/AU2010/000677 WO2010132959A1 (en) 2009-05-21 2010-05-21 Use of dynamin ring stabilizers

Publications (2)

Publication Number Publication Date
CA2762600A1 CA2762600A1 (en) 2010-11-25
CA2762600C true CA2762600C (en) 2018-05-15

Family

ID=43125677

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2762600A Active CA2762600C (en) 2009-05-21 2010-05-21 Use of dynamin ring stabilizers

Country Status (8)

Country Link
US (1) US8809386B2 (enExample)
EP (1) EP2432465B1 (enExample)
JP (1) JP2012527407A (enExample)
CN (1) CN102481280A (enExample)
AU (1) AU2010251703B2 (enExample)
BR (1) BRPI1010941B1 (enExample)
CA (1) CA2762600C (enExample)
WO (1) WO2010132959A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2782643A1 (en) * 2011-11-23 2014-10-01 The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin Androgen receptor ligands
WO2014063205A1 (en) * 2012-10-26 2014-05-01 The University Of Queensland Use of endocytosis inhibitors and antibodies for cancer therapy
JP2017518312A (ja) * 2014-06-05 2017-07-06 ユニバーシティ・オブ・カンザス マルメリン類似体および癌治療における使用方法
CN105510592A (zh) * 2014-09-26 2016-04-20 中国医学科学院基础医学研究所 梗阻性肾病的蛋白标志物
US11028138B2 (en) * 2016-07-02 2021-06-08 Virongy L.L.C. Compositions and methods for using actin-based peptides to modulate cellular bioactivity and cellular susceptibility to intracellular pathogens
CN113801872A (zh) * 2021-10-11 2021-12-17 杭州师范大学 一种精准调控组装制备稳定酶蛋白环的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL107736A (en) 1993-11-24 2001-01-11 Yissum Res Dev Co Pharmaceutical composition for the prevention of septic shock and for the treatment of chronic inflammatory diseases
WO2001064880A2 (en) 2000-02-28 2001-09-07 Millennium Pharmaceuticals, Inc. Human dynamin 40322
CN1938013A (zh) * 2003-11-21 2007-03-28 纽卡斯尔大学研究协会有限公司 抑制发动蛋白依赖性的细胞内摄作用的方法和药剂
WO2005049009A1 (en) 2003-11-21 2005-06-02 The University Of Newcastle Research Associates Limited Methods and agents for inhibiting dynamin-dependent endocytosis
WO2007056435A2 (en) 2005-11-08 2007-05-18 The General Hospital Corporation Dynamin mediated diseases and associated methods and products
US9144594B2 (en) 2005-11-08 2015-09-29 University Of Miami Cathepsin L mediated diseases and associated methods and products
WO2009034464A2 (en) 2007-09-12 2009-03-19 Newcastle Innovation Limited Indole related compounds with physiological activity

Also Published As

Publication number Publication date
EP2432465A1 (en) 2012-03-28
BRPI1010941B1 (pt) 2021-06-22
US20120122968A1 (en) 2012-05-17
AU2010251703A1 (en) 2011-12-08
US8809386B2 (en) 2014-08-19
EP2432465B1 (en) 2015-07-22
EP2432465A4 (en) 2013-01-02
CA2762600A1 (en) 2010-11-25
AU2010251703B2 (en) 2015-12-24
WO2010132959A1 (en) 2010-11-25
JP2012527407A (ja) 2012-11-08
CN102481280A (zh) 2012-05-30
BRPI1010941A2 (pt) 2019-04-09

Similar Documents

Publication Publication Date Title
Coskuner-Weber et al. Intrinsically disordered proteins and proteins with intrinsically disordered regions in neurodegenerative diseases
EP2432465B1 (en) Use of dynamin ring stabilizers
Ge et al. The ER–Golgi intermediate compartment is a key membrane source for the LC3 lipidation step of autophagosome biogenesis
EP2544688B1 (en) Methods and compositions for treatment of angelman syndrome
Kakinen et al. Single-molecular hetero-amyloidosis of human islet amyloid polypeptide
Foley et al. Trapping and characterization of nontoxic Aβ42 aggregation intermediates
Lin et al. TFEB agonist clomiphene citrate activates the autophagy-lysosomal pathway and ameliorates Alzheimer's disease symptoms in mice
US20240299409A1 (en) Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors
WO2000078145A1 (en) Macrophage scavenger receptor antagonists
JP2007521255A (ja) タンパク質凝集疾患を治療するための方法
WO2018195491A1 (en) Compositions and methods for the treatment of amyotrophic lateral sclerosis
AU2020412324A1 (en) Combination of a proteasome inhibitor and a HDAC inhibitor and its use for the treatment of genetic diseases linked to a protein conformational disorder
AU2014357521B2 (en) Identification of a new polypeptide hormone for maintenance of optimal body weight and blood glucose
US9045434B1 (en) Compositions and methods of treatment for myocilin glaucoma by selectively inhibiting GRP94
US20240083951A1 (en) Targeting alpha2delta-1-bound glutamate receptors for treating diseases and disorders
US20250074951A1 (en) Compositions and methods for altering amyloid precursor protein (app) processing
KR100833728B1 (ko) 칼시뉴린의 항상적 활성화 저해제
US20240301386A1 (en) Soluble Guanylyl Cyclase (GC1) Mimetic Polypeptides and Methods of Use Thereof
O’Brien Investigation of 1, 4-Quinone Bioisosteres and the Synthesis of Bolinaquinone Analogues as Clathrin Inhibitors
Trofimenko Novel insights into direct translocation and endocytosis of cell-penetrating peptides
US6878521B1 (en) Fibril-blocking peptide, a method for preventing fibril formation
Chamberland NECAP2-driven fast recycling controls cell migration and cancer cell invasion
Rizvi Investigating the pathophysiological mechanisms linked to 2 membrane proteins: the choline transporter 1 and the kidney anion exchanger 1
Ching Molecular domains in the peripheral myelinated nerve
Murphy Structural determinants of post-transcriptional protein regulation as modulators of monoamine signaling

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150520

H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20241125